[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 925
Citations 0
News From the Food and Drug Administration
July 7, 2015

New Therapies for Irritable Bowel Syndrome

JAMA. 2015;314(1):17. doi:10.1001/jama.2015.6855

Two new medications manufactured by separate companies have gained FDA approval for treating irritable bowel syndrome with diarrhea (IBS-D) in adults.

One of the drugs, eluxadoline, which is marketed as Viberzi, activates receptors in the nervous system that can lessen bowel contractions. In 2 randomized, double-blind, placebo-controlled trials involving 2425 patients, eluxadoline was more effective than placebo in simultaneously reducing abdominal pain and improving stool consistency over 26 weeks of treatment. The most common adverse effects associated were constipation, nausea, and abdominal pain (http://1.usa.gov/1dAfFBH).

First Page Preview View Large
First page PDF preview
First page PDF preview
×